Immatics N.V., a German biotech, focuses on training T-cells to target cancer ... that is intended to engage a more potent antitumor immune response. At the SITC meeting in November, this second ...
These therapies use genetically engineered immune cells to specifically target tumor antigens, offering a high degree of precision and minimizing damage to healthy tissue . Additionally ...
Most clinically relevant T-cell receptor (TCR)-engineered T cells are typically tested in immunocompromised mice, allowing human T-cell engraftment but failing to replicate the complex interactions of ...